ArticleBMC microbiology2025
Identification and expression of a novel antimicrobial peptide Gloverin and its antibacterial effect against Staphylococcus aureus.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antibacterial mechanisms of terpinen-4-ol against Aeromonas hydrophila.Archives of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAntimicrobial peptides (AMPs) have attracted extensive attention in various fields. Gloverin is a group of AMPs derived from Lepidoptera insects. In this study, a novel gloverin CpGlv was identified through sequence alignment. The open reading frame (ORF) of mature CpGlv, devoid of its signal peptide region, was recombinantly expressed in Escherichia coli. The antibacterial activity of the fusion protein CpGlv against Staphylococcus aureus (S. aureus) was then assessed by determining the minimum inhibitory concentration (MIC) and using scanning electron microscopy (SEM) to observe the ultrastructure of S. aureus cells. Furthermore, the effects of CpGlv on the cell wall and membrane permeability of S. aureus were evaluated by detecting the leakage of intracellular nucleic acids, proteins, alkaline phosphatase (ALP), and β-galactosidase, as well as through the propidium iodide (PI) staining experiment. Finally, the influence of CpGlv on the S. aureus biofilm formation was investigated using the crystal violet staining assay.
resultsThe results showed that the ORF of CpGlv contained a nucleotide sequence of 591 bp. The expressed fusion protein CpGlv had a molecular weight of approximately 24 kDa. The purified CpGlv exhibited significant antibacterial activity against S. aureus, with a MIC of 40 µg/mL. 2×MIC of CpGlv caused S. aureus cells to exhibit adhesion, swelling, deformation, and even rupture. Further, CpGlv resulted in the leakage of intracellular nucleic acids, proteins, ALP, and β-galactosidase in S. aureus. After PI staining, there was intracellular fluorescence intensity in S. aureus treated by CpGlv. Additionally, 1/4×MIC of CpGlv significantly reduced the biofilm formation of S. aureus.
conclusionA novel gloverin CpGlv was identified, expressed, and purified, and the recombinant CpGlv exhibited antimicrobial activity against S. aureus by increasing the cell membrane and wall permeability, and inhibiting the biofilm formation, laying a foundation for in-depth research on the antibacterial mechanism and application of CpGlv.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.